As far as we know, apart from the current report, only several other studies to date have assessed the clinical value of RRM2 protein [26,27] or mRNA [28,29,30,31] in pancreatic cancer cohorts, and these studies have varied with regard to the impact of RRM2 on patient survival. This evidence concerns the gene RRM2 and familial pancreatic carcinoma.